ORPHA:279919
Infectious posterior uveitis
Publications
332
71.9th percentile
Trials
3
Interventional, condition-specific
Researchers
969
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare ophthalmic disorder characterized by inflammation of the posterior uveal tract (retina and choroid), due to an infectious . Presenting symptoms are decreased visual acuity, visual field defects, floaters, photopsia, photophobia, and occasionally pain. Signs on examination include conjunctival injection, keratic precipitates, retrolental cells, inflammatory infiltrates on the retina, macular edema, and peripheral retinal neovascularization, among others. Complications (such as cataracts, band keratopathy, glaucoma, cystoid macula edema, and retinal detachment) may lead to permanent vision loss.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017209
- UMLS:C5230265
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
332 matched papers (249 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
3 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
332
332 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
332 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
249 in the last 10 years · high confidence · 71.9th percentile (publications denominator)
Phrase hits: 332 · MeSH hits: 0
Who's working on it?
969
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01de-la-Torre A8 papers · 2025
NeURos research group, Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia. alejadelatorre@yahoo.com.
Papers in Europe PMC - 02Agarwal A5 papers · 2026
Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE).
Papers in Europe PMC - 03Conrady CD5 papers · 2025
Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE.
Papers in Europe PMC - 04Pleyer U5 papers · 2024
Eye Clinic - Charité Universitaetsmedizin-Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Electronic address: uwe.pleyer@charite.de.
Papers in Europe PMC - 05Agrawal R4 papers · 2026
National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
Papers in Europe PMC - 06Gupta V4 papers · 2026
Advanced Eye Centre, Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Papers in Europe PMC - 07Schlaen A4 papers · 2026
Department of Ophthalmology, Hospital Universitario Austral, Derqui-Pilar, Argentina.
Papers in Europe PMC - 08Smith JR4 papers · 2025
College of Medicine and Public Health, and Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia. justine.smith@flinders.edu.au.
Papers in Europe PMC - 09Yeh S4 papers · 2025
Department of Ophthalmology, University of Nebraska Medical Center, Omaha, NE.
Papers in Europe PMC - 10Appukuttan B3 papers · 2024
Flinders University, Adelaide, Australia; Oregon Health & Science University, Portland, Oregon, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; none in our sample are currently recruiting. 13 trials are registered for posterior uveitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).
high confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: posterior uveitis
13
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07423442·NOT YET RECRUITING·Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant
Not reviewed·Conditions: Noninfectious Posterior Uveitis · Uveitis, Posterior · Uveitic Macular Edema·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 8 · after dedupe 8 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 8 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (8)
- isrctn·ISRCTN13314346·No longer recruiting·Intracorneal prosthesis for corneal blindness
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96250868·Recruiting·Gene therapy study to assess the safety, tolerability and effectiveness of AXV-101 when injected into the eye in patients with a mutated BBS1 gene to prevent sight loss
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59733193·No longer recruiting·ReNEW: a clinical trial investigating the efficacy and safety of elamipretide in subjects who have dry age-related macular degeneration (Dry AMD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15871371·No longer recruiting·A study to assess the safety, biological activity, tolerability and processing by the body of RO7200394 in participants with macular edema secondary to central retinal vein occlusion
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15180871·No longer recruiting·A study of gevokizumab in subjects with Behçet’s disease uveitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN03110798·No longer recruiting·Comparing the Efficacy and Safety of Indomethacin 0.1% Eyedrops versus Ketorolac 0.5% Eyedrops in Ocular Inflammation After Cataract Surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN42639823·No longer recruiting·Combination photodynamic treatment and intravitreal ranibizumab versus intravitreal ranibizumab alone in neovascular age-related macular degeneration
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46576063·No longer recruiting·Tacrolimus monotherapy for uveitis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Infectious posterior uveitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Infectious posterior uveitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Infectious posterior uveitis"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"posterior uveitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:44:54.560Z
